Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00697515 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Workplace Environment Study of Lisdexamfetamine Dimesylate (LDX) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3 study, sponsored by Shire.
- Completed
- Registry status
- Phase 3
- Development phase
- 142
- Enrollment target
NCT00697515 is a Phase 3 study that has completed, run by Shire. The registered enrollment target is 142 participants.
The verdict
NCT00697515, a Phase 3 study, has completed, sponsored by Shire.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 142 participants
- Enrollment target
Study Summary
To evaluate the efficacy of LDX compared to placebo in adults with ADHD in the adult workplace environment (AWE) setting
Interventions
- DRUG Placebo
- DRUG LDX
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 142 participants |
| Start Date | 2008-07-18 |
| Est. Completion | 2008-12-20 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00697515
The ClinicalTrials.gov registry entry for NCT00697515 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 142 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00697515 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00697515 about?
NCT00697515 is a clinical study titled "Safety and Efficacy Workplace Environment Study of Lisdexamfetamine Dimesylate (LDX) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)". To evaluate the efficacy of LDX compared to placebo in adults with ADHD in the adult workplace environment (AWE) setting
What is the current status of trial NCT00697515?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 142 participants. The study started on 2008-07-18. Estimated completion is 2008-12-20.
What interventions are being tested in trial NCT00697515?
The interventions under investigation include: Placebo (DRUG), LDX (DRUG).
Who is sponsoring clinical trial NCT00697515?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.